The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

详细信息查看全文

作者：Henrik H. Hansen^a ; ^{hbh@gubra.dk" class="auth_mail" title="E-mail the corresponding author} ; Pernille Barkholt^a ; Katrine Fabricius^a ; Jacob Jelsing^a ; Dick Terwel^b ; Charles Pyke^c ; Lotte Bjerre Knudsen^c ; Niels Vrang^a ; ^{niels@gubra.dk" class="auth_mail" title="E-mail the corresponding author}
关键词：Tauopathy ; Alzheimer&rsquo ; s disease ; hTauP301L transgenic mouse ; Phosphorylated tau ; GLP-1 receptor agonist ; Liraglutide
刊名：Brain Research
出版年：2016
出版时间：1 March 2016
年：2016
卷：1634
期：Complete
页码：158-170
全文大小：1698 K

文摘

class="label">•: The GLP-1 receptor is a potential novel therapeutic target in Alzheimer’s disease (AD).
class="label">•: We studied the GLP-1 receptor agonist, liraglutide, in a mouse model of tauopathy.
class="label">•: Liraglutide improves neurological function and lowers phospho-tau burden in this model.
class="label">•: Liraglutide may have therapeutic utility in the treatment of AD and other tauopathies.